Standard BioTools Return On Tangible Equity 2010-2024 | LAB

Standard BioTools return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

Standard BioTools Return On Tangible Equity 2010-2024 | LAB

Standard BioTools return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
Tempus AI (TEM)$8.5B
Inspire Medical Systems (INSP)$5.3B
Hims & Hers Health (HIMS)$5.1B
Privia Health (PRVA)$2.5B
Enovis (ENOV)$2.5B
IRhythm Technologies (IRTC)$2.4B
Azenta (AZTA)$2B
Omnicell (OMCL)$2B
Clover Health Investments (CLOV)$1.6B
10x Genomics (TXG)$1.6B
Schrodinger (SDGR)$1.4B
Phreesia (PHR)$1.1B
Butterfly Network (BFLY)$650M
Talkspace (TALK)$522M
Fulgent Genetics (FLGT)$520M
Definitive Healthcare (DH)$483M
Health Catalyst (HCAT)$459M
TruBridge (TBRG)$244M
Pulmonx (LUNG)$237M
SOPHiA GENETICS SA (SOPH)$214M
American Well (AMWL)$122M
EUDA Health Holdings (EUDA)$107M
P3 Health Partners (PIII)$75M
HeartBeam (BEAT)$67M
111 (YI)$53M
CareCloud (CCLD)$46M
Zepp Health (ZEPP)$40M
SHL Telemedicine (SHLT)$40M
Outset Medical (OM)$39M
Movano (MOVE)$20M